key: cord-0044585-v1qduxeb
authors: BENVENISTE, ETTY N.
title: Astrocyte—Microglia Interactions
date: 2012-12-02
journal: Astrocytes
DOI: 10.1016/b978-0-12-511370-0.50019-9
sha: e309b916ac0fae363c28ae1403eb982082d87d5a
doc_id: 44585
cord_uid: v1qduxeb

nan

In this chapter, the focus is on various neurological disease states in which glial cells may contribute to inflammation and immunological events occurring in the CNS. The ability of glial cells to both respond to and synthesize a variety of cytokines within the CNS; the capacity of glial cells to acquire MHC antigens and function as antigen-presenting cells within the CNS; and interactions between astrocytes and microglia are described. The implications of cytokine secretion and antigen presentation by glial cells will be discussed with respect to intracerebral immune responses and inflammation in neurological diseases that have an immunological or auto immune component.

There are two major subgroups of glial cells: the macroglia, which consist of astrocytes, oligodendrocytes, and ependymal cells, and the microglia. The functional properties of astrocytes are covered in some detail in other chapters.

Microglia constitute approximately 10% of the total glial cell population and are considered as the resident macrophage of the brain (for review, see Perry and Gordon, 1988) . Most of the current evidence strongly suggests that microglia arise from mesodermal tissues, ultimately develop from bone marrow cells, in particular, the monocyte (Perry and Gordon, 1988; Hickey and Kimura, 1988) , and populate the CNS after it has been vascularized. Thus, they can be considered as a specialized subtype of tissue macrophage found in the CNS. Different names have been given to microglia because of their variable morphologic appearance. The major subtypes of microglia include ramified, ameboid, and perivascular microglia. Ramified microglia appear as a highly branched small cell, with branching occurring in all planes. The branching of microglial cell processes is often found around neurons, suggesting that there may be a functional significance to this physical association. Perivascular microglia are found in the perivascular space and are thought to be more closely related to monocytes than to ramified microglia. Hickey and Kimura (1988) demonstrated by a chimeric model system that perivascular microglia are derived from blood monocytes. Ameboid microglia have a similar morphology as perivascular microglia and can be unipolar or bipolar. In inflammatory conditions, the ameboid microglia becomes activated and proliferates, ultimately forming microglial nodules as seen in patients with viral encephalitis and AIDS Dementia Complex (ADC) (Price et al, 1988) .

All known phenotypic markers for microglia are shared with other cell types: thus, there are no microglia-specific antigens. Microglia can be identified by a number of cell-surface antigens, including immunoglobulin Fc receptors and type 3 complement receptors (Perry et al, 1985) and β-2 integrins (Akiyama and McGeer, 1990) .

The major known function of microglia is as a scavenger cell, acting to phagocytose cellular debris, which may be important for tissue modeling in the developing CNS (Perry and Gordon, 1988) . Also, microglia may be involved with inflammation and repair in the adult CNS due to their phago cytic ability, release of neutral proteinases, and production of oxidative radicals. As will be discussed later, microglia have been demonstrated to express MHC antigens upon activation, act as antigen-presenting cells, se crete a number of immunoregulatory cytokines, and respond to cytokine stimulation, suggesting an involvement with inflammatory and immune responses within the CNS.

In MS and EAE, microglia have been shown to phagocytose myelin debris by two pathways: lysosomal degradation and receptor-mediated phagocytosis, which involves IgG as the ligand (Prineas and Graham, 1981; Epstein et al, 1983) . ADC is due to HIV-1 infection of the CNS. Overwhelm ing evidence indicates that perivascular microglia and multinucleated mi croglia are infected by HIV-1 (Watkins et al., 1990) , and a number of cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) may activate and enhance HIV replication in these cells (Osborn etal, 1989) . Whether or not the clinical symptoms and pathology of ADC are linked to altered microglia function within the CNS is not known at this time.

Cells of the immune system mediate multiple processes including elimina tion of foreign pathogens, neutralization of toxins, and killing of tumor cells. The hallmark of an immune response is antigen specificity, which lies in the specific cellular recognition of foreign antigens. This specificity is conferred by the two major classes of lymphocytes, Τ cells and Β cells, which contain in their unique surface receptors the molecular basis for antigenic specificity.

Cells of the immune system originate from pluripotent hematopoietic stem cells in the bone marrow, which give rise to two different cell lineages: the lymphoid cells, which are the precursors of Β cells and Τ cells, and the myeloid cells, which give rise to monocytes (macrophages), neutrophils, eosinophils, erythrocytes, granulocytes, and mast cells.

The two classes of lymphocytes, Τ cells and Β cells, differ in their functional properties. Τ cells are responsible for cell-mediated immunity as well as coordinating the functions of various other cell types, including Β cells and macrophages. Τ cells can be broadly divided into two subsets, both of which have antigen-specific T-cell receptors (TCR) on their surface. Tcytotoxic cells, identified by the surface molecule CD8, can destroy virusinfected cells or tumor cells. The TCR on CD8 + cells recognizes foreign antigen in conjunction with class I MHC. The second type of Τ cell, Thelper cells, regulate the ability of Β cells to produce and secrete immuno globulin and are critical for the initiation of immune responses. T-helper cells, identified by the surface molecule CD4, recognize antigen in associa tion with class II MHC molecules. Β cells are primarily effector cells; they secrete antigen-specific immunoglobulin molecules that mediate humoral immunity. Β cells also express cell-surface immunoglobulins, which function as specific antigen receptors.

Macrophages are a third class of cells (accessory cells) that do not possess any specific antigen-recognition capacity but are critical for the functioning of the immune system. Macrophages play an essential role in the process of antigen presentation to Τ cells by allowing T-cell recognition of foreign antigens and also provide to both Τ cells and Β cells the extracellular signals (cytokines) required for their functional activation.

Cooperation between the different lymphoid cells (T cells and Β cells) and macrophages, or other antigen-presenting cells (APC), is required for the initiation, perpetuation, and ultimate downregulation of an immune response (Fig. 1) . The initial activation of Τ helper cells depends on the ability of the T-helper cell (via its antigen-specific TCR) to recognize foreign antigen in association with class II MHC on an APC. Cytokines such as IL-1 are also produced by APC and are required for co-stimulation of T-helper cells. Once activated, T-helper cells proliferate and expand. These Τ cells then help Β cells proliferate, differentiate, and ultimately secrete immuno globulin molecules. Antigen-specific Τ cell help to Β cells may be delivered by cytokines or direct cellular interactions. Activated T-helper cells also release cytokines such as interferon-y (IFN-γ), which activates macrophages, and cooperate with T-cytotoxic cells in their recognition of virally infected cells or allogeneic grafts. The actual existence of T-suppressor cells is contro versial; however, researchers believe that they can act as regulatory cells to suppress ongoing immune responses, presumably by the release of sup pressive soluble mediators (Green et al, 1983 ).

Cytokines play a critical role in the initiation, propagation, regulation, and suppression of immune and inflammatory responses. Although cytokines comprise a diverse group of proteins, they share a number of generalized characteristics. Cytokines are produced during the effector phases of immu nity and serve to mediate and regulate immune and inflammatory responses. Cytokine production is usually transient; expression is initiated by activation \ Immunoglobulin secretion of gene transcription, and cytokines are rapidly secreted, resulting in a "burst" of cytokine release. An individual cytokine can be produced by many different cell types and have multiple effects on different cell types.

Cytokines have also been shown to have redundant functions (i.e., several cytokines, most notably IL-1 and TNF-α can mediate common events). Thus, a hallmark of the cytokine system is that it displays pleiotropism and redundancy. Cytokines can influence both the synthesis and function of other cytokines, resulting in complex regulatory pathways that can be either stimulatory or inhibitory. Cytokines initiate their action by binding to specific cell-surface receptors on target cells. These receptors show high affinities for their ligands, with dissociation constants in the range of 10~1 0 -10~1 2 M. The ultimate response of a target cell to a particular cytokine is determined by the level of expression of the cytokine receptor and by the nature of the coupling between the receptor and the intracellular signal transduction pathway of the target cell.

Tumor necrosis factor-a (TNF-α) is a 17,000-dalton polypeptide synthe sized primarily by activated macrophages during host responses to microbial infection (for review, see Beutler and Cerami, 1989) . The major cellular source of TNF is the activated macrophage, although many other cell types, including astrocytes and microglia, can be stimulated to secrete TNF-α. TNF-α is the principal mediator of the host response to gram-negative bacteria and also participates in inflammatory responses. TNF-α can alter vascular endothelial cell function, leading to active participation of this cell type in inflammation. Specifically, TNF-α enhances the permeability of endothelial cells (Brett et aL, 1989) , increases expression of various adhesion molecules (Pober et aL, 1986) , and enhances local adhesion of neutrophils, monocytes, and lymphocytes to endothelial cell surfaces (Pohlman et aL, 1986) , thereby facilitating transendothelial migration of immune cells and establishment of leukocyte-rich inflammatory infiltrates. TNF-α stim ulates many cell types to produce cytokines, including IL-1, IL-6, colonystimulating factors (CSFs), and TNF-α itself. TNF-α can also regulate immune responses by modulating the expression of class I and II MHC molecules on a variety of cell types, among them astrocytes and microglia. Complementary DNA cloning studies have resulted in the identification of two distinct TNF-α receptors, the 55,000-and 75,000-dalton TNF-α recep tors (Smith et aL, 1990) . The intracellular portions of the two receptors have structural differences, which suggests that perhaps the two receptors may activate different intracellular signaling pathways.

Interleukin-l(IL-l) is a 17,000-dalton polypeptide produced by many cell types including macrophages, endothelial cells, Β cells, epithelial cells, keratinocytes, microglia, and astrocytes (for review, see Arai et aL, 1990) . There are two forms of IL-1 (a and β), which are the products of two different genes. Although these two forms of IL-1 have less than 30% structural homology to one another, they both bind to the same surface receptor and have essentially identical biological activities. IL-1 is the major co-stimulator for T-cell activation via the augmentation of both IL-2 and IL-2 receptor expression. These effects allow antigen-stimulated Τ cells to rapidly proliferate and expand in number. IL-1 is a principal participant in inflammatory reactions through its induction of other inflammatory metabo lites such as prostaglandin, collagenase, and phospholipase A 2 . In addition, similar to TNF-α, IL-1 acts on endothelial cells to promote leukocyte adhe sion. IL-1 stimulates numerous cell types to produce various cytokines, such as IL-6, TNF-α, CSFs, and IL-1 itself. The mouse IL-1 receptor consists of an extracellular IL-1 binding domain (319 amino acids), a membrane spanning domain (21 amino acids), and a cytoplasmic domain (217 amino acids), which is critical for signal transduction.

Interleukin-6 (IL-6), along with IL-1 and TNF-α, is a pleiotropic cytok ine involved in the regulation of inflammatory and immunologic responses (for review, see Kishimoto, 1989; van Snick, 1990) . IL-6, a 26,000-dalton molecule, is secreted by a wide range of cells including fibroblasts, mono cytes, Β cells, endothelial cells, Τ cells, microglia, and astrocytes. Depending on the cell type, synthesis of IL-6 is induced by a variety of stimuli including the cytokines IL-1, TNF-α and IFN-γ. IL-6 is the principal cytokine for inducing terminal differentiation of activated Β cells into immunoglobulinsecreting plasma cells. A minor function of IL-6 is as a co-stimulator of Τ cells and of thymocytes. The human IL-6 receptor has an external ligandbinding domain (340 amino acids) and an intracellular domain of 80 amino acids. An IL-6 receptor antibody immunoprecipitates a 130,000-dalton pro tein (gpl30) that does not bind IL-6 itself but, rather, plays an important role in signal transduction by interacting with the external domain of the IL-6 receptor.

Interferon-γ (IFN-γ), or immune interferon (17,000 daltons), is pro duced predominantly by activated CD4 + and CD8 + Τ cells, although natural killer cells are also capable of secreting IFN-γ (for review, see Ijzermans and Marquet, 1989) . IFN-γ is a pleiotropic cytokine with antiviral activ ity, antiproliferative effects, and immunomodulatory effects. These im mune effects include activation of mononuclear phagocytes, enhancing the generation of toxic oxygen radicals by macrophages, modulating both class I and II MHC expression on a wide range of cells, and promoting dif ferentiation of both Τ cells and Β cells. The IFN-γ receptor has an extra cellular domain, membrane-spanning domain, and cytoplasmic domain. However, the IFN-γ receptor protein itself cannot transduce a biological signal, suggesting that additional components are required for signal trans duction.

As mentioned previously, during human diseases such as viral encephalitis (Moench and Griffin, 1984) , MS (Traugott et al, 1983) , and ADC (Navia et al, 1986) and animal models of CNS disease such as EAE (Raine, 1984) , inflammatory infiltrates comprised of activated Τ cells, Β cells, and macro phages are found in the CNS. Numerous studies have demonstrated that cytokines are present in the CNS during neurological diseases: (1) IL-1, IFN-γ, IL-2, TNF-α, and lymphotoxin have been localized in sections of multiple sclerosis (MS) brain (Hofman et al, 1986 (Hofman et al, , 1989 Traugott and Lebon, 1988; Selmaj et al, 1991a) , particularly in the MS plaque region;

(2) IL-1 is present in brain from patients with Down's syndrome and Alzhei mer's disease and appears to be localized in microglia (Griffin et al, 1989) ;

(3) transforming growth factor-/3 has been localized in both the astrocyte and microglia in the brains of ADC patients (Wahl et al, 1991) ; (4) IFNy and IL-6 have been detected in cerebrospinal fluid (CSF) during viral menin gitis and encephalitis (Frei et al, 1988 ); (5) increased CSF levels of IL-6 and TNF-α have been documented in patients with MS and other inflammatory neurological diseases (Sharief et al., 1991; Maimone etal., 1991) ; and (6) in creased IL-6 levels have been found in the CNS of mice suffering acute EAE (Gijbels et al., 1990 ) (for summary, see Table I ). The presence of these cytokines has been attributed to production by activated lymphoid and mononuclear cells that have infiltrated the CNS as well as the activation of endogenous glial cells such as the astrocyte and microglia. Studies were initiated to investigate whether or not factors from immune cells may be contributing to the astrocytic proliferation and/or activation seen in the region of inflammatory infiltrates in diseases such as MS. Fontana et al. (1982a) tested this hypothesis by examining the ability of lymphocytes to produce glial-stimulating factors in vitro. Supernatants from activated rat lymphocytes were collected and tested for glial-stimulating activity. Indeed, they found that these supernatants enhanced both RNA synthesis and DNA synthesis in rat astrocyte cultures. This factor, named glial-stimulating fac tor, was produced by both activated rat Τ lymphocytes and Β lymphocytes. A factor with similar activity was also derived from mitogen-activated human Τ lymphocytes (Fontana, 1982c) . The availability of recombinant cytokines has greatly facilitated the study of cytokine influences on glial cell function, because the use of crude cell-derived supernatants is always complicated by the fact that numerous cytokines can be present in these preparations. The following sections sum marize what is known about the effects of recombinant IL-1, TNF-α, IFNy, and IL-6 on glial cell function.

A. Interleukin-1

As mentioned earlier, IL-1 affects a wide range of target cells and is considered an important mediator of inflammatory responses. IL-1 appears to also mediate inflammation associated with injury to the brain. Because one response to brain injury is proliferation of astrocytes, IL-1 was tested for its capacity to induce proliferation of these cells. Purified IL-1 was shown to have a stimulatory activity for astrocyte growth in vitro (Giulian and Lachman, 1985) , whereas IL-1 directly injected into the brain can stimulate astrogliosis (Giulian et al, 1988) . These results suggest that IL-1, released by inflammatory cells, may contribute to astroglial scarring in damaged mammalian brain. As will be discussed later, both activated astrocytes and microglia secrete an IL-1-like molecule. This would provide an endogenous brain source of IL-1, which could promote astrogliosis and the development of immune responses within the CNS.

IL-1 can increase intracellular adhesion molecule 1 (ICAM-1) expres sion on human astrocytes (Frohman etal, 1989) . The expression of adhesion molecules is thought to facilitate the ability of the astrocyte to function as an APC in the CNS and influence intracerebral immune responses. This is particularly important because the expression of ICAM can enhance the ability of an APC to present antigen when the number of MHC molecules on the cell surface is low, suggesting that the combined expression of ICAMs and class II MHC may be synergistic in eliciting a more potent immune response. IL-1 is also a strong inducer of cytokine production by astrocytes. IL-1 stimulation of primary rat astrocytes results in the secretion of TNFα ) and IL-6 (Frei et al., 1989; , whereas human astroglial cell lines will produce CSFs (Tweardy et al, 1990) , TNF-α (Bethea et al, 1990 (Bethea et al, , 1992 , and IL-6 (Yasukawa et al, 1987) in response to IL-1. These cytokines (IL-1, TNF-α, IL-6) have wide ranging effects on glial cells themselves.

Components of the complement cascade have been implicated in con tributing to the pathology of several neurological autoimmune diseases such as MS, experimental allergic encephalomyelitis (EAE), and Guillain-Barre syndrome (for review, see Shin and Koski, 1992) . For example, the levels of terminal complement components have been shown to fluctuate in MS disease exacerbations and remissions, suggesting C9 consumption. Recent studies have indicated that astrocytes can serve as a local endogenous source of some of the complement components, notably C3, the central component of the complement cascade (Levi-Strauss and Mallat, 1987) . We have re cently shown that IL-1 β can enhance C3 expression in both human astroglioma cells and primary rat astrocytes (Barnum et al., 1992b) . Thus, IL-1/3 generated during the inflammatory stages of diseases such as MS and EAE may enhance complement production by the astrocyte.

Little is known about the biological effect of IL-1 on microglia and oligodendrocytes, although microglia are capable of secreting IL-1 (Giulian etal., 1986) .

Fontana et al. (1982a,c) had demonstrated that soluble factors from lymphoid cells could modulate the growth of glial cells, and they were interested in determining whether the reciprocal could occur (i.e., whether glial cells might secrete soluble factors that would regulate lymphoid-mono nuclear cells or glial cells themselves). They discovered that cultured murine astrocytes, upon stimulation with lipopolysaccharide (LPS), secreted signifi cant amounts of prostaglandin and an IL-1-like factor (Fontana^ al., 1982b) and that human glioblastoma cell lines also constitutively secreted an IL-1like molecule (Fontana et al., 1984b) . Both rat and murine microglia are also capable of producing IL-1 in response to LPS stimulation (Giulian et al., 1986; Malipiero et al., 1990) , and virally transformed microglia clones pro duce IL-1 (Righi et al., 1989) . These findings indicate that there are two endogenous local sources of IL-1 within the CNS: the astrocyte and the microglia. Giulian et al. (1986, 1988) propose that microglia are the more likely source of IL-1 during acute phases of brain injury, because microglia, are the first brain cells to appear in increased numbers at sites of trauma or infection. Activated astrocytes can then produce IL-1, and this type of circuitry provides a potential autocrine mechanism for astrocytic growth, which may be critical in the promotion of astroglial scarring in diseased or traumatized brain. Table II summarizes the effects of IL-1 on glial cells.

The best-characterized experimental model for CNS autoimmune dis ease is EAE. This disease is induced by injection of myelin basic protein (MBP) or transfer of encephalitogenic MBP-specific Τ cells to naive recipi ents. EAE is characterized by an inflammatory infiltration of the CNS by

Induces proliferation of neonatal astrocytes, human astroglioma cells Induces ICAM-1 expression on human fetal and adult astrocytes Induces IL-6 expression by neonatal astrocytes, human astroglioma cell lines Induces TNF-α expression in conjunction with IFN-γ by neonatal rat astrocytes Induces TNF-α expression in human astroglioma cell lines Induces G-CSF and GM-CSF expression in human astroglioma cell lines Astrocytes make IL-1 in response to LPS stimulation Human glioblastoma cells constitutively secrete IL-1 Enhances expression of C3 complement component in rat astrocytes, human astroglioma Microglia Microglia make IL-1 in response to LPS stimulation activated Τ lymphocytes and macrophages, demyelination, and acute, chronic, or chronic relapsing paralysis. The mediators of this disease are MBP-reactive T-helper cells, which are class IIMHC-restricted (for review, see Zamvil and Steinman, 1990 ). Cross et al. (1990) have proposed that antigen-specific autoimmune Τ cells are responsible for initiation of disease and that perpetuation of disease may be the result of an influx of largely nonantigen-specific inflammatory cells of the recipient animal. Susceptibility to EAE appears to be linked to MHC alleles, although non-MHC genes may play a small role in contributing to EAE (Gasser et al., 1973) . Due to the known inflammatory effects of IL-1 and the knowledge that glial cells can produce IL-1 within the CNS, there has been interest in the role of IL-1 in EAE. IL-1 has been shown to enhance the in vitro activation of encephalitogenic Τ cells, thereby enhancing the adoptive transfer of EAE (Mannie et al., 1987) . More recently, Jacobs et al. (1991) demonstrated that in vivo administration of IL-1 enhanced the severity and chronicity of clinical paralysis associated with EAE, whereas treatment of animals with soluble mouse IL-1 receptor (an IL-1 antagonist) significantly delayed the onset of EAE, reduced the severity of paralysis and weight loss, and shortened the duration of disease. These results suggest a role for IL-1 in inflammatory CNS disease states such as EAE. Because IL-1 does have varied effects on endothelial and glial cells such as expression of adhesion molecules, cytokine induction, and proliferation, the inhibition of IL-1 activity by soluble IL-1 receptor may prevent further CNS inflammation and injury. It is speculated that the use of soluble IL-1 receptors as an IL-1 antagonist may be therapeu tically beneficial in diseases such as MS.

As mentioned previously, interferon-γ (IFN-γ) is the product of activated Τ cells and, thus, would be present in the CNS only during disease states where the blood-brain barrier has been breached and activated Τ cells have   TABLE II lnterleukin-1 and Glial Cells infiltrated into that site. I FN-γ has been shown to interact with astrocytes and microglia and functions in part by modulating MHC gene expression on these cells. Brain cells such as astrocytes and microglia have been shown to constitutively express low levels of class I antigens (Wong et al., 1984) , whereas IFN-γ induces a substantial increase in the expression of class I antigens on these cell types, in a wide variety of species (rat, mouse, human) (Wong et al, 1984; Suzumura et al, 1986) . The direct injection of IFN-γ into the brains of mice also enhances class I MHC expression in vivo (Wong etal., 1984) . Class I antigens are involved in antigen recognition by cytotoxic Τ cells, which usually results in destruction of class I-positive cell targets. The implication of enhanced class I MHC antigen expression on glial cells by IFN-γ is that they can be rendered susceptible to lysis by class I-restricted cytotoxic Τ lymphocytes (CTL). Astrocytes in vitro can serve as targets for class I MHC-specific cytotoxicity mediated by CTL (Skias et al., 1987) .

Astrocytes and microglia do not constitutively express class II MHC antigens; however, IFN-γ can induce the expression of class II MHC mole cules on these cells (Fierz et al., 1985; Fontana^ al., 1984a) . In vitro, research ers have demonstrated that both astrocytes and microglia can present anti gen to Τ cells in an MHC-restricted manner, resulting in T-cell activation (Fontana^a/., 1984a; YreietaL, 1987) . The implication of class II expression on glial cells, and their antigen-presenting capability, is that these cells may stimulate the development of aberrant immune responses within the CNS, possibly autoimmune reactions. This hypothesis, however, requires the pres ence of activated, IFN-y-secretingTcells within the CNS. Massac al., (1986) showed that viral infection of astrocytes (hepatitis virus and measles virus) also results in the expression of class II antigens. This provides a mechanism for astrocyte class II expression that is independent, at least initially, of activated Τ cells and IFN-γ secretion. In light of the fact that lymphocyte-monocyte traffic through the brain is normally limited, the cerebral endothelium, which in part maintains the blood-brain barrier, is thought to be important in the induction of immune responses, because lymphocytes may first encounter brain antigens on these cells. In fact, endothelial cells in vitro can express class II antigens upon treatment with IFN-γ (Male et al., 1987) and present antigen (Male et ai, 1987; McCarron et al., 1985) . Class II MHC-positive endothelial cells could then act as the first antigen-presenting cells encountered by blood-borne Τ cells, resulting in activation of these cells. These activated Τ cells would then be able to penetrate the blood-brain barrier in a variety of fashions such as passing through altered tight junctions between the endothelial cells or by dissolving the extracellular matrix pro duced by endothelial cells. Once activated Τ cells have penetrated the blood-brain barrier, the secretion of IFN-γ within the CNS could then act as a signal for class II MHC expression on astrocytes and microglia. Class II-positive glial cells could then act as antigen-presenting cells, leading to further activation of Τ lymphocytes and, in concert with IL-1 production by astrocytes and microglia, create an environment for local immune re sponses within the CNS.

Recent studies from our laboratory have focused on understanding the intracellular signaling events involved in IFN-γ induction of class II MHC expression by astrocytes. Our results indicate that both IFN^-induced acti vation of protein kinase C (PKC) and enhanced sodium influx are required for class II MHC gene expression in the astrocyte (Benveniste et al, 1991) . The PKC activator, phorbol myristate acetate (PMA) could not mimic the action of IFN-γ, indicating that activation of PKC alone is not sufficient to induce class II MHC expression. In this regard, data from our laboratory indicate that a ΙΡΝ-γ-enhanced nuclear protein is critical for transcription of the class II MHC gene in astrocytes (Moses et al, 1992) and that PMA is not capable of inducing this protein (Panek and Benveniste, unpublished observation). These results suggest that PKC activation alone by PMA is not sufficient to induce this nuclear protein and that ΙΡΝ-γ-induced intracellular signals are more complex than those induced by PMA.

Although class II expression on astrocytes has been conclusively demon strated in vitro, in vivo studies have yielded contradictory findings. Direct injection of IFN-γ into the brains of mice induced class II antigens on astrocytes, indicating that astrocytes have the potential to express these antigens in vivo (Wong et al, 1984; Vass and Lassmann, 1990) . Many labora tories have examined whether or not astrocytes express class II antigens in a variety of immune-mediated disease states to better understand the possi ble role of the astrocyte as a local APC. Traugott and Lebon (1988) , by immunohistochemical techniques and light microscopy, demonstrated class II expression on astrocytes in active chronic MS lesions. A study by Hofman et al (1986) also identified class II-positive astrocytes in MS brain by doublestaining. Immunocytochemistry and electron microscopic analysis of CNS tissue from three patients with acute and chronic progressive MS indicate that some astrocytes are class II MHC-positive and can act as phagocytic cells in the CNS, providing evidence that the astrocyte may indeed function as an APC . In SJL mice with acute or chronic relapsing EAE, some class II-positive cells were identified as astrocytes (Sakai et al, 1986) ; however, other studies investigating the EAE model in Lewis rats failed to detect class II-positive astrocytes in the brain (Hickey et al, 1985; Vass et al, 1986) and found only class II-positive microglia. These conflicting results may indicate that the ability of astrocytes to function as APC in vivo may only be relevant in certain diseases or disease models. A recent study (Vass and Lassman, 1990) demonstrates that upon intrathecal injection of IFN-γ, there is a progressive appearance of class II MHC-positive cells within the CNS, which may determine antigen recognition during different phases of inflammatory disease. The number of class II-positive microglia increases substantially after IFN-γ injection, whereas astrocytes express class II antigens inconsistently, with a low density and patchy distribution. The authors propose that class II-positive microglia play an important role in the initiation of antigen presentation within the CNS, whereas class IIpositive astrocytes are involved in propagating immune reactions in the CNS. Another possibility may be the loss of class II-positive astrocytes by class II MHC-restricted T-cell cytotoxicity, as shown by Sun and Wekerle (1986) , which could explain the loss of astrocvtes sometimes reported in EAE.

Another potential explanation for the paucity of class II-positive astrocytes in disease states compared to class II-positive microglia is that class II expression on astrocytes is more readily subject to downregulation. Sasaki et al. (1990) demonstrated that increases in cyclic AMP (cAMP) levels will inhibit astrocyte, but not microglia, class II expression. Norepinephrine has been shown to inhibit astrocyte class II MHC via /3 2 -adrenergic receptormediated increases in cAMP (Frohman^a/., 1988) . Thus, expression of class II on astrocytes may be more susceptible to downregulation by endogenous agents like norepinephrine, and, as such, expression may be more transient on the astrocyte compared to microglia.

Correlation with Experimental Allergic Encephalomyeliti s EAE appears to be strain-specific because Brown-Norway rats and BALB/c or C57BL/6 mice are resistant whereas Lewis rats and SJL mice are susceptible. Several studies have examined what might contribute to the immunopathological reaction seen in the CNS of susceptible animals. Massa etal. (1987a,c) demonstrated that astrocytes derived from susceptible strains express much higher levels of class II antigens upon treatment with either IFN-γ or virus compared to astrocytes prepared for EAE-resistant strains. This hyperinduction of class II in EAE-susceptible animals was astrocytespecific as both peritoneal macrophages and microglial cells of susceptible and resistant strains showed identical patterns for class II induction. This differential expression of class II on astrocytes compared to microglia sug gests that regulation of class II expression on astrocytes may correlate with disease development in the CNS.

IFN-γ can increase the expression of ICAM-1 adhesion molecules on human astrocytes, in a similar fashion to IL-1 enhancement of ICAM-1 (Frohman et al., 1989) . Primary rat astrocytes express one class of high-affinity TNF-α receptors, which are increased in number upon exposure to IFN-γ (Benveniste et al, 1989) . As IFN-γ and TNF-α often synergize for mediating biological effects, the ability of IFN-γ to increase TNF-α receptor expression may contribute, in part, to the synergy observed between these two cytokines.

IFN-γ does not appear to induce directly cytokine production by astrocytes but provides a "priming signal," which renders the astrocyte responsive to a subsequent exposure to other cytokines. For example, nei ther IFN-γ nor IL-Ιβ alone induce TNF-α production by primary rat astrocytes, but they act together in a synergistic fashion to induce TNF-α expression . More importantly, astrocytes pretreated with IFN-γ, then exposed to IL-1/3, produce more TNF-α com pared to the simultaneous addition of both cytokines, whereas cells pre treated with IL-1/3, then exposed to IFN-γ, produce negligible levels of TNF-α. This suggests that IFN-γ generates a priming signal for the astrocytes, which then increases their sensitivity to a subsequent exposure to IL-1/3. These studies also emphasize the complexity of cytokine interactions, demonstrating that different responses depend on the temporal sequence of cytokine encounter. IFN-γ alone has no effect on IL-6 production by astrocytes but enhances the ability of IL-1/3 to induce IL-6 expression (Ben veniste et al, 1990) . The nature of the IFN^-induced priming signal(s) is unknown at this time.

IFN-γ can enhance expression of the complement component C3 in both human astroglioma cells and primary rat astrocytes (Barnum et al, 1992a) . This is particularly interesting because IFN-γ either inhibits or has no effect on C3 expression in other cell types such as hepatocytes, mono cytes, and endothelial cells. Thus, the IFN-γ mediated increase in C3 gene expression may be unique to the astrocyte. The effects of IFN-γ on glial cells are summarized in Table III .

TNF-α has a diverse range of functions in the CNS due to its influence on astrocytes, oligodendrocytes, and endothelial cells. TNF-α has been shown to mediate myelin and oligodendrocyte damage in vitro (Selmaj and Raine, 1988) and has cytotoxic activity against rat oligodendrocytes, which results in cell death (Robbins et al., 1987) . This aspect of TNF-α activity could certainly contribute to myelin damage and/or the demyelination process seen in diseases such as MS, EAE, and ADC. Lymphotoxin (LT), a cytokine genetically related to TNF-α, exerts a much more potent cytotoxicity toward oligodendrocytes than TNF-α and mediates its effect via apoptosis (Selmaj et al., 1991b) . Thus, two cytokines, TNF-α and LT, cause cell death of the oligodendrocyte. TNF-α also has multiple noncy to toxic effects on the astrocyte and may function in an autocrine manner as astrocytes express specific high-affinity TNF-α receptors (Benveniste et ai, 1989) and secrete TNF-α (Lieberman et al., 1989; Chung and Benveniste, 1990) . TNF-α in creases class I MHC expression on astrocytes (Lavi et al., 1988) , thereby making the astrocyte a more susceptible target for class I-restricted CTL (Skias et al., 1987) . TNF-α alone has no influence on astrocyte class II expression but acts to enhance class II MHC expression induced by IFN-γ or virus (Massa et al., 1987b; Benveniste et al., 1989) . TNF-α functions by increasing IFN-y-induced transcription of the class II gene, rather than having an effect on class II messenger RNA (mRNA) stability (Vidovic et ai, 1990) . TNF-α, like IFN-γ and IL-1, also induces ICAM-1 expression on astrocytes (Frohman et al., 1989) . The effect of TNF-α on both class II MHC and ICAM-1 expression would contribute to the ability of the astrocyte to function as an APC within the CNS. TNF-α has a mitogenic effect on both primary astrocytes (Selmaj et al., 1990 ) and human astroglioma cell lines (Lachman et ai, 1987; Bethea et al., 1990) , which is thought to contribute to the reactive astrogliosis associated with various neurological diseases. TNF-α also has a multitude of effects on endothelial cells, which func tion as an interface between blood and surrounding tissues and are critical for maintaining homeostasis. TNF-α has been shown to alter endothelial cell function, leading to the active participation of this cell type in inflammatory reactions. Specifically, TNF-α enhances the permeability of endothelial cells (Brett et al., 1989) , increases ICAM-1 expression (Pober et al., 1986) , and enhances local adhesion of lymphocytes and monocytes to endothelial cell surfaces (Pohlman et al., 1986) . The architecture of the blood-brain barrier with astrocytic processes abutting onto cerebrovascular endothelium, sug gests that astrocyte-derived TNF-α may influence neighboring endothelial cells, alter blood-brain barrier permeability, and promote inflammatory infiltration into the CNS.

TNF-α induces cytokine production by astrocytes. Astrocytes respond to TNF-α by secreting IL-6 Frei et al., 1989) , a pleiotropic cytokine involved in B-cell differentiation and immunoglob-ulin synthesis (van Snick, 1990) . Astrocytes also produce granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colonystimulating factor (GM-CSF) in response to TNF-α (Malipiero et al, 1990) . G-CSF/GM-CSF can augment inflammatory responses by attracting granu locytes and macrophages to migrate to inflammatory sites in the CNS, by promoting their survival in these sites, and by increasing their effector function. Additionally, GM-CSF can induce the proliferation and activation of microglia (Frei et al, 1987) . Finally, astrocytes stimulated with TNF-α express TNF-α mRNA, suggesting a positive feedback loop for TNF-α expression (Chung and Benveniste, unpublished observation) .

There are two endogenous sources of TNF-α within the CNS: the astrocyte and the microglia. TNF-α production is induced in astrocytes by multiple stimuli. These include (i) treatment with LPS (Robbins et al, 1987; Lieberman et al, 1989; Chung and Benveniste, 1990) , (ii) exposure to the cytokines IFN-γ and IL-1/3 Bethea et al, 1992) , (iii) exposure to the neurotropic paramyxovirus, Newcastle disease virus (Lieberman et al, 1989) , and (iv) treatment with phorbol ester and calcium ionophore (Bethea et al, 1990) . Mouse microglia produce TNF-α in response to LPS or IFN-γ (Frei et al, 1987) . Although numerous published reports have described astrocyte TNF-α production, some controversy re mains as to whether or not the astrocyte is the true producer of TNF-α, with the concern that residual contaminating microglia are actually the source of TNF-α in these cultures. The findings that human astroglioma cell lines express mRNA for TNF-α and synthesize biologically active TNF-α upon stimulation implicate the astrocyte as a source for TNF-α (Bethea et al, 1990 (Bethea et al, , 1992 . See Table IV for a summary of the effects of TNF-α on glial cells.

Cytokine production has been implicated in contributing to autoim mune diseases (for review, see Sinha et al, 1990) . Because cytokines play a major role in regulating immune responses, aberrant expression may be a factor in the initiation and perpetuation of autoimmunity. Of particular interest is the fact that the genes for TNF-α and functionally related TNFβ (LT) map within the MHC gene complex. Because many autoimmune diseases such as EAE are strongly associated with class II MHC gene prod ucts, TNF-α and TNF-β are plausible candidates for cytokines involved with autoimmunity.

We have recently demonstrated that astrocytes from EAE-susceptible and -resistant rat strains differ in their ability to produce TNF-α (Chung et al, 1991) . Astrocytes from EAE-resistant BN rats express TNF-α in response to LPS alone, yet IFN-γ does not significantly enhance LPS-induced TNF-

Increases class I MHC expression on primary astrocytes Enhances class II MHC expression induced by IFN-γ or virus on primary astrocytes Induces ICAM-1 expression on human fetal and adult astrocytes Induces proliferation of adult astrocytes, human astroglioma cell lines Induces IL-6 production by primary astrocytes Induces G-CSF and GM-CSF production by primary astrocytes Astrocytes make TNF-α in response to LPS, virus, IFN-y/IL-l Human astroglioma cells make TNF-α in response to IL-1, PMA, calcium ionophore Express high affinity TNF-α receptors Enhances expression of C3 complement component in rat astrocytes, human astroglioma Microglia

Cell death Myelin damage α expression, nor do they express appreciable TNF-α in response to the combined stimuli of IFN-y/IL-1/3. In contrast, astrocytes from Lewis rats (EAE-susceptible) express low levels of TNF-α in response to LPS and are extremely responsive to the priming effect of IFN-γ for enhanced TNF-α gene expression. Also, Lewis rat astrocytes produce TNF-α in response to IFN-y/IL-lj8. The differential TNF-α production by astrocytes from BN and Lewis strains is not due to the suppressive effect of prostaglandins, because the addition of indomethacin does not alter the differential pattern of TNF-α expression. Furthermore, Lewis and BN astrocytes produce an other cytokine, IL-6, in response to LPS, IFN-γ, and IL-1/3 in a comparable fashion. Peritoneal macrophages and neonatal microglia from Lewis and BN rats are responsive to both LPS and IFN-γ priming signals for subse quent TNF-α production, suggesting that differential TNF-α expression by the astrocyte is cell type-specific. The capacity for TNF-α production by Lewis astrocytes, especially in response to disease-related cytokines such as IFN-γ and IL-1/3, may contribute to disease susceptibility and to the inflammation and demyelination associated with EAE.

Circumstantial evidence for the role of TNF-α and TNF-β in EAE was obtained from studies demonstrating that the ability of encephalitogenic T-cell clones to transfer disease was positively correlated with the amount of TNF-α/β cytotoxic activity (Powell etal., 1990) . More conclusive evidence was recently obtained by Ruddle et al. (1990) , in which they demonstrated that an antibody to TNF-α/β could prevent the transfer of EAE by encephalitogenic T-cells. These findings indicate that inhibition of the biological activities of these two cytokines can prevent neurological disease, although the mechanism(s) of action is as yet unknown.

IL-6 has been demonstrated to have multiple effects on the astrocyte. IL-6 has a mitogenic effect (Selmaj et al, 1990) and may contribute to reactive gliosis. Astrocytes respond to IL-6 by secreting nerve growth factor, which induces neural differentiation (Frei et al, 1989) . IL-6 has been shown to inhibit TNF-α production by monocytes (Aderka et al, 1989) . As astrocytes and microglia can secrete TNF-α, and TNF-α induces IL-6 pro duction by the astrocyte, this may represent a negative regulatory pathway for controlling TNF-α expression in the CNS.

Another possible role of IL-6 in the CNS may relate to B-cell differentia tion. Ample evidence indicates B-cell stimulation during various neurologi cal diseases, as evidenced by immunoglobulin synthesis within the CNS and large amounts of immunoglobulin found within CSF (Tourtellotte and Ma, 1978; Resnick et al, 1985) . IL-6 has been detected in CSF during viral meningitis and encephalitis (Frei et al, 1988) . Increased IL-6 levels have been found in the CNS of mice suffering acute EAE (Gijbels et al, 1990) , and intracerebroventricular injection of IL-1/3 in rats induces high circulat ing levels of IL-6 (de Simoni et al, 1990) . Intracerebral production of IL-6 by astrocytes and microglia (see below), the cytokine known to induce the terminal differentiation of Β cells into immunoglobulin-secreting plasma cells, may contribute in part to heightened humoral immune responses detected in the CNS during various neurological diseases.

Primary rat and murine astrocytes can secrete IL-6 in response to a variety of stimuli including virus, IL-1, TNF-α, IFN-γ plus IL-1, LPS, and calcium ionophore (Frei et al, 1989; Lieberman et al, 1989; . The human astrocytoma cell line, U373, and glioblastoma line, SK-MG4, express IL-6 mRNA in response to IL-1 (Yasukawa et al, 1987) . Mouse microglia will secrete IL-6 upon infection with virus or stimulation with the cytokine macrophage colony-stimulating factor (Frei et al, 1989) , whereas transformed microglia clones also produce IL-6 (Righi et al, 1989) . Similar to IL-1 and TNF-α, there are two endogenous CNS sources for IL-6: the astrocyte and the microglia. These two cells types, however, appar ently are responsive to different stimuli for IL-6 production as murine microglia do not produce IL-6 in response to IL-1 or TNF-α, whereas

Induces proliferation of astrocytes Enhances NGF production by primary astrocytes Astrocytes make IL-6 in response to LPS, IL-1, TNF-α, IFN-y/IL-1, virus, calcium ionophore Human glioma cells make IL-6 in response to IL-1 Microglia Microglia make IL-6 in response to M-CSF, virus murine astrocytes do (Frei et al, 1989) . Table V summarizes the effects of IL-6 on glial cells.

Because of the diverse biological activities of IL-6, and the variety of stimuli by which IL-6 is produced, attention has recently been focused on regulation of IL-6 gene expression. The IL-6 promoter region contains several important transcriptional control element motifs, including an AP-1 binding site; a sequence similar to the human c-fos serum response element (SRE); a core sequence of the cAMP-responsive element; and a sequence homologous to the NF-κΒ binding site (for review, see Kishimoto, 1989) . A number of studies utilizing the promoter region of the IL-6 gene linked to a reporter gene, as well as deletion mutants of the IL-6 promoter region, have identified several as-acting elements involved in the inducibility of the IL-6 gene. These ^include an IL-1 response element homologous to the c-fos SRE in a human glioblastoma line (Isshiki et al, 1990) . Interestingly, we have found that the NF-κΒ binding site is critical for both IL-1 and TNF-α induction of IL-6 in primary rat astrocytes and that both IL-1 and TNF-α induce an NF-/cB-like protein in astrocytes .

Thus, it appears that there are differences in the as-acting DNA elements involved in IL-6 gene regulation in human glioblastoma cells and primary astrocytes.

This review highlights the fact that cells of the immune system and CNS share similar functions: (1) secretion of immunoregulatory cytokines, (2) response to cytokines, and (3) antigen presentation. These properties allow for both physical contact between the two systems (i.e., microglia and/ or astrocytes presenting antigen to Τ cells) and communication by soluble factors such as cytokines. A complex circuitry of interactions is mediated by cytokines, especially in the event of lymphoid-mononuclear cell infiltration into the CNS. The secretion of IFN-γ by infiltrating activated Τ cells could initially induce astrocytes and microglia to express class I and class II MHC antigens as well as prime these cells for subsequent cytokine production, contributing to either the initiation and/or propagation of intracerebral immune responses. A number of inflammatory mediators known to be in the CNS such as prostanglandin, the cytokines IFN-α and IFN-/3, TGF/3, and neuropeptides like norepinephrine can function to ultimately suppress immune responses by inhibiting class I and II MHC expression and cytokine production by glial cells.

The induction and ultimate downregulation of immune responses and cytokine production within the CNS depend on (1) a dynamic interaction between a variety of peripheral immune cells and CNS cell types, (2) the activational status of these cells, (3) the presence of cytokines with pleiotropic effects (IFN-γ, IL-1, IL-6, TNF-α, etc.), (4) the concentration and location of these cytokines in the CNS, and (5) the temporal sequence in which a particular cell responds to the cytokines. Figure 2 depicts some of the potential interactions between peripheral immune cells and cells of the CNS but is by no means a comprehensive picture. The ultimate outcome of immunological and inflammatory events in the CNS will be determined, in part, by an interplay of the preceding parameters.

The majority of the studies reviewed here reflect the capacity of cultured primary glial cells or glial cell lines to function in vitro. How these activities correlate to the true functions of these cells in vivo during pathological conditions is difficult to assess at this time. Finally, future studies on the cellular and molecular mechanisms involved with MHC and cytokine expres sion by glial cells-specifically (1) the nature of the second-messenger signals utilized by astrocytes and microglia, (2) delineating specific ds-acting DNA regulatory elements and nuclear proteins involved with MHC and cytokine expression by glial cells, and (3) characterizing cytokine receptors on glial cells-will aid us in better understanding bidirectional communication be tween the immune and nervous systems.

IL-6 inhibits lipopolysaccharide-induced tumor necro sis factor production in cultured human monocytes, U937 cells, and in mice

Brain microglia constitutively express beta-2 integrins

Cytokines: Coordinators of immune and inflammatory responses

Interferon-gamma regulation of C3 gene expression in human astroglioma cells

Interleukin-1 and tumor necrosis factor mediated regulation of C3 gene expression in human astroglioma cells: Synergism with gamma-interferon Glia

Tumor necrosis factor-α enhances interferon-γ mediated class II antigen expression on astrocytes

Induction and regulation of interleukin-6 gene expression in rat astrocytes

Interferon-γ induced astrocyte class II major histocompatibility complex gene expression is associated with both protein kinase C activation and sodium entry

Tumor necrosis factor production and receptor expression by a human astroglioma cell line

Interleukin-1/3 induction of tumor necrosis factor-alpha gene expression in human astro glioma cells

The biology of cachectin/TNF-A primary mediator of the host response

Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mecha nism involving regulatory G proteins

Tumor necrosis factor-alpha production by astrocytes: Induction by lipopolysaccharide, interferon-gamma and interleukin-1./ Immu nol

Differential TNF-α expression by astrocytes from experimental allergic encephalomyelitis susceptible and resistant rat strains

Homing to central nervous system vasculature by antigen-specific lymphocytes

Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6

Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis

Astrocytes as antigen presenting cells. I. Induction of la antigen expression on astrocytes by Τ cells via immune interferon and its effect on antigen presentation

Glia cell stimulating factor (GSF): A new lymphokine. Part 1: Cellular sources and partial purification of murine GSF, role of cytoskeleton and protein synthesis in its production

Production of prostaglandin Ε and an interleukin-1-like factor by cultured astrocytes and C6 glioma cells

Glia cell stimulating factor (GSF): A new lymphokine. Part 2: Cellular sources and partial purification of human GSF

Astrocytes present myelin basic protein to encephalitogenic T-cell lines

Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2-mediated effects

Antigen presentation and tumor cytotoxicity by interferon-y-treated microglial cells

Production of Β cell stimulatory factor-2 and interferon-γ in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients

On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases

Norepinephrine inhibits y interferon-induced major histocompatibility class II (la) antigen expression on cultured astrocytes via /32-adrenergic signal transduction mechanisms

The induction of intracellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-?, tumor necrosis factor-α, lymphotoxin, and interleukin-1: Relevance to intracerebral antigen presentation

Genetic control of susceptibil ity to experimental allergic encephalomyelitis in rats

Interleukin 6 production in the central nervous system during experimental autoimmune encephalo myelitis

IL-1 stimulation of astroglial proliferation after brain injury

Interleukin-1 of the central nervous system is produced by ameboid microglia

IL-1 injected into mammalian brain stimulates astrogliosis and neovascularization

Immunoregulatory T-cell pathways

Brain interleukin 1 and S-100 immunoreac tivity are elevated in Down syndrome and Alzheimer disease

Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo

Expression of la molecules by astrocytes during acute experimental allergic encephalomyelitis in the Lewis rat

Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain

Tumor necrosis factor identified in multiple sclerosis brain

Interferon-gamma: A review

Constitutive and interleukin (IL-l)-inducible factors interact with the IL-1-responsive element in the IL-6 gene

Experimental autoimmune encephalomyelitis is exacerbated by IL-1 α and suppressed by soluble IL-1 receptor

The biology of interleukin-6

Growth promoting effect of recombinant interleukin-1 and tumor necrosis factor for a human astrocytoma cell line

Tumor necrosis factor induces expression of MHC class I antigens on mouse astrocytes

Multiple sclerosis: A role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study

Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation

Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared

Production of hemopoietic colony-stimulat ing factors by astrocytes

Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating ex perimental autoimmune encephalomyelitis in lewis rats

Viral particles induce la antigen expression on astrocytes

Inducibility of la antigen on astrocyte by murine coronavirus JHM is rat strain dependent

Tumor necrosis factor amplifies virus-mediated la induction on astrocytes

Hypersensitivity of la antigen on astrocytes correlates with strain-specific susceptibility to experimental autoimmune en cephalomyelitis

Presentation of myelin basic protein by murine cerebral vascular endothelial cells

Immunocytochemical identification and quantitation of the mononuclear cells in the cerebrospinal fluid, meninges, and brain during acute viral meningoencephalitis

Usage of primary cells to delineate IFN-γ responsive DNA elements in the HLA-DRA promoter and to identify a novel IFN-γ enhanced nuclear factor (IFNEX)

The AIDS dementia complex

Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor KB

Macrophages and microglia in the nervous system

Immunohistochemical localization of macrophages and microglia in adult and developing mouse brain

Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon

An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-α increases neutrophil adherence by a cd 18-dependent mechanism

Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific Τ cell clones correlates with encephalitogenicity

The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex

Multiple sclerosis: Capping of surface immunoglobulin-G on macrophages engaged in myelin breakdown

Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis

Biology of disease: Analysis of autoimmune demyelination: Its impact upon multiple sclerosis

Intra-blood-brain barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex

Monokine production by microglial cell clones

Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

Ia expression in chronic relapsing experimental allergic encephalomyelitis induced by long-term cultured Τ cell lines in mice

Differential suppression of interferon-γinduced Ia antigen expression on cultured rat astroglia and microglia by second messen gers

Tumor necrosis factor mediates myelin and oligodendro cyte damage in vitro

Proliferation of astrocytes in vitro in response to cytokines. A primary role for TNF

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

Cytokine cytotoxicity against oligodendrocytes: Apoptosis induced by lymphotoxin

Association between tumor necrosis factor ed and disease progression in patients with multiple sclerosis

The complement system in demyelination

Autoimmune diseases: The failure of self tolerance

Susceptibility of astrocytes to class I MHC antigen-specific cytotoxicity

A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins

Regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-KB-like nuclear protein

Ia-restricted encephalitogenic Τ lymphocytes mediating EAE lyse autoantigen-presenting astrocytes

The expression of MHC antigens on oligodendrocytes: Induction of polymorphic H-2 expression by lymphokines

Multiple sclerosis: The blood-brain barrier and the measurement of de novo central nervous system IgG synthesis

Interferon-γ and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions

Multiple sclerosis: Distribution of T-cells, T-cell subsets and la-positive macrophages in lesions of different ages

Monokine modulation of human astroglial cell production of granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor. I. Effects of IL-Ια and IL-10

Interleukin-6: An overview

Intrathecal application of interferon gamma

The distribution of Ia antigen in the lesions of rat acute experimental allergic ancephalomyelitis

Induction and regulation of class II MHC mRNA expression in astrocytes by IFN-γ and TNF-α

Macrophage-and astrocyte-derived transforming growth factor β as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome

Specific tropism of HIV-1 for microglial cells in primary human brain cultures

Inducible expression of H-2 and la antigens on brain cells

Structure and expression of human Β cell stimulatory factor-2 (BSF-2/IL-6)

The Τ lymphocyte in experimental allergic encephalo myelitis